Previous 10 |
CMP-001 in combination with pembrolizumab continues to demonstrate durable responses in anti-PD-1 refractory melanoma Encouraging new data on pathological responses and 1-year RFS with neoadjuvant CMP-001 and nivolumab in resectable Stage III melanoma CAMBRIDGE, Mass.,...
Checkmate Pharmaceuticals (NASDAQ: CMPI ) : Q2 net loss of $8.3M Press Release More news on: Checkmate Pharmaceuticals, Inc., Earnings news and commentary, ,
Successfully completed IPO in August 2020 raising $76.6 million in gross proceeds On track to initiate planned new clinical trials in melanoma and head and neck cancer CAMBRIDGE, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Chec...
Total gross proceeds raised by Checkmate in IPO of $86.25 million (including sale of overallotment shares) Intention to use part of the net proceeds from the IPO to fund the development of its product candidate CMP-001, an asset Checkmate has in-licensed from Kuros Kuros to receive ...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . Economic reports in the week ahead Investors will have their eyes on economic reports covering construction spending, manufacturing a...
News, Short Squeeze, Breakout and More Instantly...
Checkmate Pharmaceuticals Inc. Company Name:
CMPI Stock Symbol:
NASDAQ Market:
Checkmate Pharmaceuticals Inc. Website:
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules • $2.5 million of milestone to be paid to XOMA Corporation under royalty agreement SCHLIEREN (ZURICH), Switzerland, June 02, 2022 (GLOBE NEWSWIRE) -- Kuros Biosciences AG (“Kuros” ...
CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat c...
CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today an...